Publicaciones en las que colabora con MARIO DELGADO MORA (51)

2022

  1. Editorial: The innate immune system in rheumatoid arthritis

    Frontiers in Immunology

2003

  1. PACAP in immunity and inflammation

    Annals of the New York Academy of Sciences

  2. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease

    Gastroenterology, Vol. 124, Núm. 4, pp. 961-971

  3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia

    Journal of Leukocyte Biology, Vol. 73, Núm. 1, pp. 155-164

2002

  1. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, Núm. 2, pp. 1053-1058

  2. Pituitary adenylate-cyclase-activating polypeptide expression in the immune system

    NeuroImmunoModulation, Vol. 10, Núm. 3, pp. 177-186

  3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells.

    The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 16, Núm. 13, pp. 1844-1846

  4. Vasoactive intestinal peptide in the immune system: Potential therapeutic role in inflammatory and autoimmune diseases

    Journal of Molecular Medicine, Vol. 80, Núm. 1, pp. 16-24

2001

  1. Immunology of VIP: A review and therapeutical perspectives

    Current Pharmaceutical Design, Vol. 7, Núm. 2, pp. 89-111

  2. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: An experimental immunomodulatory therapy

    Journal of Immunology, Vol. 167, Núm. 6, pp. 3182-3189

  3. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

    Nature Medicine, Vol. 7, Núm. 5, pp. 563-568

  4. Vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide and immune system: From basic research to potential clinical application

    Biomedical Reviews, Vol. 12, Núm. 1, pp. 1-9

2000

  1. Anti-inflammatory actions of VIP/PACAP: Role in endotoxemia

    Annals of the New York Academy of Sciences

  2. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: Role in lethal endotoxic shock

    European Journal of Immunology, Vol. 30, Núm. 11, pp. 3236-3246

  3. Immunobiology of vasoactive intestinal peptide (VIP)

    Immunology Today

  4. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP

    Annals of the New York Academy of Sciences, Vol. 921, pp. 92-102

  5. VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression

    Annals of the New York Academy of Sciences, Vol. 921, pp. 68-78

1999

  1. Regulation of VIP production and secretion by murine lymphocytes

    Journal of Neuroimmunology, Vol. 93, Núm. 1-2, pp. 126-138

  2. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide

    Journal of Neuroimmunology, Vol. 99, Núm. 1, pp. 61-71

  3. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression

    Journal of Immunology, Vol. 163, Núm. 8, pp. 4213-4223